Dialog Solutions Business Update Regarding Coronavirus (COVID-19)
March 6, 2020
As we continue to monitor the spread of the novel coronavirus (COVID-19) and its global impact, we’re providing this update on Dialog Solutions’ operations.
We share your concern and are actively supporting our customers, end users and employees around the world with expanded online access and work-from-home opportunities as necessary. We have instituted a review process for all international and non-essential travel to protect travelers and provide peace of mind for our customers and employees. Our business is operating normally, with no disruption to our systems or supply chain.
Further, the steps we have already taken, along with our contingency plans, will help us to minimize any interruptions in the future:
- We have a cloud-based infrastructure that provides redundancy across geographies and our network.
- We are not experiencing any difficulty obtaining or shipping physical media. If quarantines do begin to disrupt shipments, we have plans to adjust routing or formats to minimize any delays.
- Our teams are adept at collaboration and telecommuting as part of our normal course of business, so we expect most product development – as well as support and training programs – to continue as scheduled.
We know that many of your institutions are adopting interim policies on in-person meetings, conference attendance, and so on. Our teams are proactively reaching out before visiting to ensure we respect your expectations.
Rest assured we will provide updates on our business operations as needed. However, in the meantime, if there is anything that we can do to support you and your institution, or if you have questions or concerns, please contact your account team or email us at firstname.lastname@example.org.
Dialog Solutions, Now a part of Clarivate
Searching literature is one of the most important elements of a systematic review. A well planned...
Whether you're conducting a systematic review literature search or screening literature for drug...